Laura Brass

Director/Board Member at

Immunitas Therapeutics, Inc.

Finance

Health Technology

Consumer Services

Profile

Laura Brass is currently Managing Director at Novartis Venture Funds (USA) since 2018 and at Novartis Venture Fund since 2018.
Dr. Brass is also Director at Anokion SA since 2019, and Director at Kanyos Bio, Inc. and Immunitas Therapeutics, Inc. Former roles include Managing Director at MPM BioImpact LLC from 2015 to 2018, Director-Business Development at the Office of Technology Development, Director at ESCAPE Bio, Inc., Senior Manager at Elixir Pharmaceuticals, Inc., and Senior Vice President-Business Development at TriNetX, LLC.
Education includes undergraduate studies at the University of Missouri and an MBA and a doctorate from The University of Chicago.

Laura Brass active positions

Companies	Position	Start
Novartis Venture Funds (USA) Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors	Private Equity Investor	2018-09-30
Anokion SA Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance	Director/Board Member	2019-09-10
Immunitas Therapeutics, Inc. Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Develops single cell genomic-based drugs	Director/Board Member	-
Kanyos Bio, Inc. Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes	Director/Board Member	-
Novartis Venture Funds Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors.	Private Equity Investor	2018-09-30

All active positions of Laura Brass

Former positions of Laura Brass

Companies	Position	End
MPM BioImpact LLC MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions.	Private Equity Investor	2018-09-29
ESCAPE Bio, Inc. ESCAPE Bio, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics against genetic targets for neurodegenerative disease	Director/Board Member	-
Elixir Pharmaceuticals, Inc. Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases	Corporate Officer/Principal	-
TriNetX, LLC TriNetX, LLC Data Processing ServicesTechnology Services Provides healthcare and life science data & platform solutions	Corporate Officer/Principal	-
░░░░░░ ░░ ░░░░░░░░░░ ░░░░░░░░░░░	░░░░░░░ ░░░░░░ ░░░░░░░░	░░░░░░░░░░

See the detail of Laura Brass's experience

Training of Laura Brass

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Laura Brass's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	12
MPM BioImpact LLC MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions.	Finance
University of Missouri University of Missouri Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Elixir Pharmaceuticals, Inc. Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases	Miscellaneous
The University of Chicago The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Novartis Venture Funds Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors.	Finance
Office of Technology Development Office of Technology Development Investment ManagersFinance Office of Technology Development invests in companies located in the United States. The firm focuses on health and technology sectors. It participates in early-stage transactions.	Finance
Novartis Venture Funds (USA) Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors	Finance
Anokion SA Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance	Health Technology
TriNetX, LLC TriNetX, LLC Data Processing ServicesTechnology Services Provides healthcare and life science data & platform solutions	Technology Services
Kanyos Bio, Inc. Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes	Health Technology
ESCAPE Bio, Inc. ESCAPE Bio, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics against genetic targets for neurodegenerative disease	Health Technology
Immunitas Therapeutics, Inc. Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Develops single cell genomic-based drugs	Health Technology